Photo taken on Aug. 23, 2021 shows Pfizer signage at Pfizer's World Headquarters in New York, United States. (Photo by Michael Nagle/Xinhua)
A Pfizer-BioNTech booster dose showed a relative vaccine efficacy of 95.6 percent when compared to those who did not receive a booster, according to a trial.
WASHINGTON, Oct. 21 (Xinhua) -- Pfizer and BioNTech announced Thursday that a large-scale trial of their COVID-19 vaccine booster showed it restored full protection against the disease.
In a Phase 3 randomized, controlled trial, a Pfizer-BioNTech booster dose was administered to more than 10,000 individuals 16 years of age and older, who previously received the Pfizer-BioNTech primary two-dose series.
It showed a relative vaccine efficacy of 95.6 percent when compared to those who did not receive a booster.
These are the first efficacy results from any randomized, controlled COVID-19 vaccine booster trial.
"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease," said Albert Bourla, Pfizer chairman and chief executive officer.
Last month, the U.S. Food and Drug Administration authorized the booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. ■
